These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 3804379

  • 1. Effects of LS-2616 administration upon the autoimmune disease of (NZB x NZW) F1 hybrid mice.
    Tarkowski A, Gunnarsson K, Stålhandske T.
    Immunology; 1986 Dec; 59(4):589-94. PubMed ID: 3804379
    [Abstract] [Full Text] [Related]

  • 2. Effect of FUT-175, a new synthetic protease inhibitor, on the development of lupus nephritis in (NZB x NZW) F1 mice.
    Ikehara S, Shimamura K, Aoyama T, Fujii S, Hamashima Y.
    Immunology; 1985 Aug; 55(4):595-600. PubMed ID: 4018844
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Successful treatment of autoimmunity in (NZB X NZW)F1 mice with cyclosporin and (Nva2)-cyclosporin: I. Reduction of autoantibodies.
    Gunn HC.
    Clin Exp Immunol; 1986 May; 64(2):225-33. PubMed ID: 3488856
    [Abstract] [Full Text] [Related]

  • 5. Azathioprine administration to NZB X NZW hybrid mice with lupus nephritis: beneficial effect complicated by development of malignant lymphomas.
    Casey TP.
    N Z Med J; 1973 Oct 10; 79(500):290-5. PubMed ID: 4519116
    [No Abstract] [Full Text] [Related]

  • 6. A diet enriched with eicosapentaenoic acid suppresses autoimmune nephritis in female (NZB x NZW) F1 mice.
    Prickett JD, Robinson DR, Steinberg AD.
    Trans Assoc Am Physicians; 1982 Oct 10; 95():145-54. PubMed ID: 6304973
    [Abstract] [Full Text] [Related]

  • 7. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32).
    Werwitzke S, Trick D, Sondermann P, Kamino K, Schlegelberger B, Kniesch K, Tiede A, Jacob U, Schmidt RE, Witte T.
    Ann Rheum Dis; 2008 Feb 10; 67(2):154-61. PubMed ID: 17557887
    [Abstract] [Full Text] [Related]

  • 8. Successful treatment of autoimmunity in MRL/1 mice with LS-2616, a new immunomodulator.
    Tarkowski A, Gunnarsson K, Nilsson LA, Lindholm L, Stålhandske T.
    Arthritis Rheum; 1986 Nov 10; 29(11):1405-9. PubMed ID: 3778545
    [Abstract] [Full Text] [Related]

  • 9. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus.
    Bahjat FR, Pine PR, Reitsma A, Cassafer G, Baluom M, Grillo S, Chang B, Zhao FF, Payan DG, Grossbard EB, Daikh DI.
    Arthritis Rheum; 2008 May 10; 58(5):1433-44. PubMed ID: 18438845
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of lupus disease by anti-double-stranded DNA antibodies of the IgM isotype in the (NZB x NZW)F1 mouse.
    Werwitzke S, Trick D, Kamino K, Matthias T, Kniesch K, Schlegelberger B, Schmidt RE, Witte T.
    Arthritis Rheum; 2005 Nov 10; 52(11):3629-38. PubMed ID: 16255055
    [Abstract] [Full Text] [Related]

  • 11. Analysis of the New Zealand Black contribution to lupus-like renal disease. Multiple genes that operate in a threshold manner.
    Drake CG, Rozzo SJ, Hirschfeld HF, Smarnworawong NP, Palmer E, Kotzin BL.
    J Immunol; 1995 Mar 01; 154(5):2441-7. PubMed ID: 7868910
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Acceleration of glomerulonephritis in NZB x NZW mice by early immunization with DNA and injection of bacterial lipopolysaccharide. Experimental approach to the treatment of lupus nephritis by use of the accelerated model of NZB x NZW mouse disease.
    Fournie GJ, Minh MG, Mignon-Conte MA, Hass S, Lambert PH, Conte JJ.
    J Clin Lab Immunol; 1980 Sep 01; 4(2):103-6. PubMed ID: 7441709
    [Abstract] [Full Text] [Related]

  • 15. Genetic studies on the skin lupus band test in New Zealand mice.
    Furukawa F, Maruyama N, Yoshida H, Hamashima Y, Hirose S, Shirai T.
    Clin Exp Immunol; 1985 Jan 01; 59(1):146-52. PubMed ID: 3871675
    [Abstract] [Full Text] [Related]

  • 16. Estrogen receptor-alpha deficiency attenuates autoimmune disease in (NZB x NZW)F1 mice.
    Bynoté KK, Hackenberg JM, Korach KS, Lubahn DB, Lane PH, Gould KA.
    Genes Immun; 2008 Mar 01; 9(2):137-52. PubMed ID: 18200028
    [Abstract] [Full Text] [Related]

  • 17. Toxoplasma gondii infection inhibits the development of lupus-like syndrome in autoimmune (New Zealand Black x New Zealand White) F1 mice.
    Chen M, Aosai F, Norose K, Mun HS, Ishikura H, Hirose S, Piao LX, Fang H, Yano A.
    Int Immunol; 2004 Jul 01; 16(7):937-46. PubMed ID: 15148287
    [Abstract] [Full Text] [Related]

  • 18. Anxiety behavior, exploratory behavior, and activity in NZB x NZW F1 hybrid mice: role of genotype and autoimmune disease progression.
    Schrott LM, Crnic LS.
    Brain Behav Immun; 1996 Sep 01; 10(3):260-74. PubMed ID: 8954598
    [Abstract] [Full Text] [Related]

  • 19. Dietary omega-3 lipids delay the onset and progression of autoimmune lupus nephritis by inhibiting transforming growth factor beta mRNA and protein expression.
    Chandrasekar B, Troyer DA, Venkatraman JT, Fernandes G.
    J Autoimmun; 1995 Jun 01; 8(3):381-93. PubMed ID: 7575999
    [Abstract] [Full Text] [Related]

  • 20. Systemic administration of interleukin-4 expressing plasmid DNA delays the development of glomerulonephritis and prolongs survival in lupus-prone female NZB x NZW F1 mice.
    Hayashi T, Hasegawa K, Sasaki Y, Mori T, Adachi C, Maeda K.
    Nephrol Dial Transplant; 2007 Nov 01; 22(11):3131-8. PubMed ID: 17670770
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.